Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
A new test for breast cancer screening, molecular breast imaging (MBI) may be more sensitive
than mammography for detecting breast cancer in women with dense breasts. The purpose of this
study is to see if MBI using a low dose of gamma radiation can find cancers not seen on
mammography.
Hypotheses: 1. Low-Dose MBI has a significantly higher sensitivity and specificity and equal
or higher positive predictive value than SM in women age 40 and older with mammographically
dense breasts. 2. Low-dose MBI has comparable sensitivity and specificity to that previously
achieved with MBI using a higher dose of radiation. 3. MBI produces a low false positive rate
(specificity >90%) that permits its use as a screening tool in this patient population.